IanFVA BRAND OF IONAFAIan Financial VisionAI-Driven. Independent. For Everyone.

Healthcare Valuations

Latest fair-value assessments and target prices by sector.

$115.46

CNC Valuation Report 2026-07-30

Centene Corporation is a diversified managed care organization focused on government-sponsored healthcare, demonstrating recent financial improvements driven by increased premiums and cost control, projecting adjusted EPS exceeding $4.80 in 2026. While facing membership softening due to Medicaid redetermination, the Illinois Medicaid contract renewal and AI-driven fraud prevention mitigate risk. Positive macroeconomic factors like stable GDP and interest rates support continued performance, though inflation remains a concern. Strategically, Centene is shifting from expansion to debt reduction, operational efficiency, and strategic acquisitions, evidenced by divestitures and a focus on Medicare Advantage and D-SNPs. Risk factors include regulatory changes, contract losses, and actuarial model accuracy. Recent balance sheet adjustments prioritize leverage reduction and shareholder returns. The company’s trajectory reflects a move towards sustainable growth through cost management, scale, and strategic capital allocation, with a focus on long-term value creation despite cyclical volatility in key performance indicators like ROE and asset turnover.

$10.99

CSBR Valuation Report 2026-07-29

Champions Oncology (CSBR) operates within personalized cancer treatment, generating revenue through preclinical services (Translational Oncology Solutions - TOS), a subscription-based data analytics platform (Lumin Bioinformatics), and direct patient access. Recent performance shows revenue growth, reaching $59.4 million in fiscal 2026 with positive adjusted EBITDA of $1.6 million, indicating improved operating leverage and a 51% oncology services margin. Strategic investments focus on radiopharmaceuticals and the Lumin platform to drive future growth. The company maintains moderate working capital intensity and is viewed cautiously by analysts, with valuation comparable to peers. Positive EBITDA and revenue growth position CSBR as a potential acquisition target, though reliance on pharmaceutical R&D spending introduces cyclicality. Financial analysis reveals a dynamic capital structure with fluctuating debt levels and a focus on reinvesting earnings for long-term growth. While demonstrating operational improvements, CSBR faces challenges in consistently translating revenue into sustained profitability, with a volatile cash burn rate and a current ratio often below industry averages. Strategic shifts prioritize innovation and data analytics, aiming for long-term earnings power, but require disciplined capital allocation and consistent execution to navigate competitive pressures and macroeconomic factors.

$114.49

GOVX Valuation Report 2026-07-29

GeoVax Labs is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, operating in a high-risk, capital-intensive sector. Revenue is currently nonexistent, reliant on successful clinical trials, regulatory approval, and eventual commercialization – likely through partnerships. Its core technology, a modified vaccinia ankara virus-like particle platform, aims for enhanced immunogenicity and safety. A diversified pipeline, including programs for COVID-19, HIV, and solid tumors, presents both opportunity and complexity, requiring substantial and sustained external funding. Recent shifts prioritize key programs like GEO-MVA and Gedeptin®, streamlining resources while acknowledging ongoing financial uncertainty. While partnerships with government agencies provide validation and non-dilutive funding, they are insufficient to cover long-term costs. Historical performance indicates a prolonged R&D period without sustained profitability. Valuation is speculative, dependent on probabilistic modeling of pipeline success and future revenue. The company faces cyclical revenue, volatile margins, and a reliance on equity financing, necessitating careful monitoring of cash burn and access to capital. While current and forecasted macroeconomic conditions offer relative stability, GeoVax must manage inflationary pressures and secure favorable financing to advance its pipeline and achieve long-term viability. Projected valuations indicate significant appreciation potential, contingent on successful execution and favorable market conditions.

$2.93

OPK Valuation Report 2026-07-29

OPKO Health is a diversified healthcare company with revenue from diagnostics (BioReference Laboratories) and pharmaceuticals. Recent performance shows narrowing losses and revenue exceeding expectations, driven by restructuring at BioReference and a China commercialization agreement. The pharmaceutical pipeline includes Rayaldee and potential growth drivers like OPK88004 and OPK88003, alongside hGH-CTP developed with Pfizer. Strategic focus includes extended-release formulations and next-generation therapies like CAR T cell programs. While losses continue, improved financial trends and raised guidance have boosted share price. Macroeconomic factors present both challenges (inflation, currency risk) and opportunities (stable GDP growth). OPKO’s strategy emphasizes cost management, clinical trial success, and effective commercialization. Over the past four quarters, the company shifted towards streamlining operations through divestitures and partnerships, prioritizing efficiency and long-term value creation. Valuation requires considering EBITDA multiples, pharmaceutical development risks, and diagnostic cyclicality. Recent financial maneuvers include asset sales, share repurchases, and debt issuance, impacting capital structure and shareholder returns. R&D investment is high, signaling a focus on innovation and future growth, but requires disciplined execution.

$204.28

UHS Valuation Report 2026-07-28

Universal Health Services (UHS) is a diversified healthcare provider with revenue driven by hospital and behavioral health services, sensitive to payer rates and patient volume. Recent financial performance showed Q2 2026 growth exceeding expectations with net income of $358.4 million, though full-year forecasts were revised downward due to Medicaid reimbursement uncertainty. Investor activity is mixed, with some increasing stakes and others reducing them. UHS demonstrates operational leverage and geographic diversification, but faces challenges from inflation, labor costs, and regulatory scrutiny. Strategic shifts include acquisitions like Talkspace and a focus on outpatient services and value-based care. While revenue is growing, maintaining EBITDA margins and managing working capital are crucial. The company’s balance sheet is strengthening through debt management and share repurchases. Macroeconomic stability is offset by inflationary pressures potentially impacting patient demand. UHS aims for sustained growth through operational efficiency, strategic capital allocation, and adapting to evolving healthcare landscapes, despite a volatile risk profile and valuation range.

$191.36

ENSG Valuation Report 2026-07-28

Ensign Group operates within the fragmented post-acute care sector, acquiring and stabilizing facilities focused on rehabilitative and long-term care, generating revenue from diverse payer sources. Recent earnings exceeded expectations, but positive momentum was overshadowed by investigations into alleged substandard patient care and questionable billing practices initiated by multiple law firms following reports from Hunterbrook Media and Muddy Waters Research. This led to a significant decline in share price, with over $500 million in market capitalization lost. Despite scrutiny, institutional investors maintain positions, though some have reduced holdings while others increased them. The company’s valuation remains within peer range, but investigations pose a material risk. Ensign’s working capital intensity is typical for the sector, and future capital allocation will be influenced by legal outcomes and care standards. Stable GDP growth is offset by inflationary pressures impacting healthcare costs, while a tight labor market challenges cost management. The company’s strategic evolution focuses on operational efficiency, real estate investment via Standard Bearer REIT, and a decentralized operating model. While demonstrating revenue growth, Ensign faces risks related to regulatory changes, legal challenges, and maintaining consistent quality of care to restore investor confidence.

$521.31

HCA Valuation Report 2026-07-27

HCA Healthcare operates a large network of hospitals and outpatient centers, generating revenue through diverse medical services. Recent financial results show 8.7% topline growth and 11% EPS increase, driven by admissions growth, despite increasing costs. However, expiring premium tax credits are shifting patients to uninsured status, increasing bad debt and impacting revenue. While benefiting from demographic trends, HCA faces headwinds from payer mix, costs, and legal inquiries. Strategic initiatives focus on cost containment, revenue cycle management, and high-margin services. Recent capital allocation includes debt management and share repurchases. Macroeconomic factors present both opportunities (stable unemployment) and challenges (inflation). HCA’s strategic shift emphasizes technology, home health, and ambulatory care to diversify revenue and improve efficiency. Valuation indicates potential for growth, with a projected 6.3% increase to $414.41 next quarter and a long-term target of $521.31, contingent on successful execution of strategic initiatives and navigating evolving healthcare regulations. The company’s financial performance is characterized by cyclical volatility and sensitivity to external factors, requiring careful monitoring of working capital and cost management.

$24.07

SMMT Valuation Report 2026-07-26

Summit Therapeutics has strategically shifted from infectious disease to oncology, focusing on ivonescimab for non-small cell lung cancer (NSCLC). This pivot involved divesting its antibiotic asset, ridinilazole, for potential $105M contingent payments, and is currently funded entirely by debt and equity, experiencing widening net losses. Ivonescimab’s Phase III data shows promising survival trends, with a BLA accepted by the FDA (PDUFA date Nov 2026) and trials underway for kidney cancer. Valuation heavily relies on ivonescimab’s success, reflected in a high-risk market capitalization and conservative discounted cash flow analyses. Recent financial performance reveals a precarious cash position and potential going concern risk, despite improved operational efficiency. The company’s strategy centers on expanding ivonescimab’s market reach, including licensing agreements for Latin America, the Middle East, and Africa. Macroeconomic factors, including stable but elevated interest rates and inflationary pressures, present challenges to funding and operational costs. SMMT demonstrates volatile but improving operating cash flow, alongside consistently negative net income and ROI/ROIC, necessitating continued capital raises and careful financial management.

$296.43

THC Valuation Report 2026-07-26

Tenet Healthcare Corporation (THC) is a diversified healthcare services provider focused on acute care and expanding into ambulatory care. Recent performance shows positive trends with 43.5% non-GAAP EPS growth and 10% ambulatory revenue increase offsetting hospital segment headwinds. Full-year revenue guidance is raised to $5.03 billion with $3.025 billion in projected free cash flow, supported by a $2 billion share repurchase program. Investor activity is mixed, with a “Moderate Buy” analyst consensus. The company maintains stable working capital but faces macroeconomic risks including inflation and regulatory changes impacting reimbursement. Strategic emphasis on higher-acuity services and ambulatory growth is key to mitigating these pressures. THC is shifting towards “second curve” growth through AI integration and operational efficiency, demonstrated by improving, though volatile, ROIC and a deleveraging balance sheet. Valuation indicates moderate dispersion with a current trading level suggesting potential short-term correction, followed by projected growth over the next one to two years, ultimately reaching a long-term target price of $296.43 contingent on sustained innovation and efficient scaling.

$369.52

WST Valuation Report 2026-07-25

West Pharmaceutical Services benefits from stable demand in the pharmaceutical supply sector, particularly for injectable drugs and increasingly, self-administered therapies like GLP-1 agonists. Recent Q2 2026 results show 13.8% revenue growth to $872.3 million, with adjusted EPS exceeding expectations at $2.37, driven by a shift towards higher-margin, high-value products now comprising 49% of revenue. Full-year forecasts have been raised to $3.345–$3.380 billion revenue and $8.85–$9.05 EPS, reflecting confidence in continued double-digit organic growth. Strategic divestitures, like the SmartDose sale, are streamlining the portfolio towards differentiated offerings. While GLP-1 demand is a near-term tailwind, concentration risk warrants monitoring. The company focuses on operational efficiency, working capital optimization, and returns capital to shareholders via a $0.22 quarterly dividend. Macroeconomic stability supports this outlook, though inflationary pressures require mitigation through pricing power and cost control. Over the past four quarters, the company has shifted from aggressive growth to a more defensive posture focused on core competencies and operational efficiency, evidenced by restructuring and portfolio optimization. Risks include crude oil price volatility, regulatory scrutiny, supply chain fragility, and competitive pressures. Despite these, WST demonstrates a strengthening economic moat and a strategic focus on high-value products, positioning it for continued revenue and margin expansion.